Skip to main content
. 2023 Aug 15;29(20):4068–4075. doi: 10.1158/1078-0432.CCR-23-0621

Figure 2.

Figure 2. A, Binimetinib and physician's choice of chemotherapy treatment groups (n = 215), Kaplan–Meier plot of progression-free survival by treatment arm and KRAS mutation status (Mut vs. WT). B, Binimetinib and physician's choice of chemotherapy treatment groups (n = 215), Kaplan–Meier plot of progression-free survival by treatment arm and MAPK alteration status. (MEK162, binimetinib; Mut, mutant; WT, wild-type; ALT, alteration). The x-axis is percentage of patient's progression-free survival; the y-axis is time in months.

A, Binimetinib and physician's choice of chemotherapy treatment groups (n = 215), Kaplan–Meier plot of progression-free survival by treatment arm and KRAS mutation status (Mut vs. WT). B, Binimetinib and physician's choice of chemotherapy treatment groups (n = 215), Kaplan–Meier plot of progression-free survival by treatment arm and MAPK alteration status. (MEK162, binimetinib; Mut, mutant; WT, wild-type; ALT, alteration). The x-axis is percentage of patient's progression-free survival; the y-axis is time in months.